Real-World check: targeted drug MIRV tested against tough ovarian cancer
NCT ID NCT07687602
First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time
Summary
This study monitors the safety and effectiveness of mirvetuximab soravtansine (MIRV) in people with a specific type of ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy and tests positive for the folate receptor-alpha protein. About 69 participants in South Korea who have already tried one to three prior treatments will receive MIRV as part of their routine care and be followed for up to 62 months. The goal is to see how well the drug works and what side effects occur in everyday clinical practice.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mirvetuximab soravtansine (MIRV)
- What this could lead to
- If successful, this could confirm that MIRV is a safe and effective treatment option for people with this hard-to-treat ovarian cancer in real-world settings.
- What could go wrong
- This is an observational post-marketing study, not a controlled trial, so results may be less definitive. Side effects are possible, and the small size (69 participants) limits general conclusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLATE RECEPTOR-ALPHA POSITIVE PLATINUM-RESISTANT FALLOPIAN TUBE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.